Inclusion Criteria:

- Stage III breast cancer disease, with histological confirmation by true-cut or
open-biopsy.

- Ages between 18 and 75 years old. Patients older than 70 must have an adequate
quality of life to be eligible.

- Patients cannot have received previous treatment with chemotherapy, hormone therapy,
radiotherapy or immune therapy.

- Performance status of 0,1, 2 (ECOG).

- At least a 6 month life expectancy.

- Neutrophils > 1500; platelets > 100000; haemoglobin > 10 mg/dL.

- Adequate renal and hepatic functions, with serum creatinine < 1.2 mg/dl and total
bilirubin < 2 mg/dl.

- Adequate contraceptive methods during the study and up to 3 months after.

- Adequate cardiac function assessed by physical exam, electrocardiogram (EKG) and left
ventricular ejection fraction (LVEF) > 55%.

Exclusion Criteria:

- Inflammatory carcinoma or stage I, II or IV breast cancer disease.

- Males.

- Active infection.

- Other neoplasms except for basal skin carcinoma or cervical in situ carcinoma
adequately treated. Other previous neoplasms are allowed if diagnosed and treated
more than 5 years before study registration.

- Concomitant serious disease provoking organ failure (heart, renal, hepatic,
respiratory).

- Pre-existing motor or sensorial neuropathy > grade 1.

- Inability for treatment compliance.

- History of hypersensitivity to compounds such as cremophor, cyclosporine or vitamin
K.

- History of arrhythmias or congestive heart failure, even when controlled; or active
cardiac blocking of second or third grade.

- History of myocardial infarction in the previous 6 months.

- Hypertension (HT) not controlled.

- Pregnant or lactating women.